HMMJ.TO - Horizons Marijuana Life Sciences ETF

Toronto - Toronto Delayed Price. Currency in CAD
18.08
+0.16 (+0.89%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close17.92
Open18.20
Bid18.05 x 0
Ask18.08 x 0
Day's Range17.81 - 18.41
52 Week Range13.43 - 27.00
Volume616,842
Avg. Volume671,838
Net Assets643.12M
NAV14.33
PE Ratio (TTM)N/A
Yield6.99%
YTD Return-19.73%
Beta (3Y Monthly)N/A
Expense Ratio (net)0.94%
Inception Date2017-04-04
  • Cannabis Stock Roundup: CGC, HEXO, TLRY, and More
    Market Realist16 hours ago

    Cannabis Stock Roundup: CGC, HEXO, TLRY, and More

    Cannabis Stock Roundup: CGC, HEXO, TLRY, and MoreCanopy Growth gets CIBC coverageIn the morning trading session at around 11:00 AM ET today, Canopy Growth (WEED)(CGC) was off to a positive start with the stock rising nearly 3.7%. The stock was

  • Price Target Update for Canopy Growth in January
    Market Realist22 hours ago

    Price Target Update for Canopy Growth in January

    Analysts' January Rating Updates for TLRY, CGC, and ACB(Continued from Prior Part)Canopy GrowthCanopy Growth (WEED) (CGC) has continued to deepen its roots in the United States with a recent announcement that could be a game changer for the company.

  • What Analysts Recommend for Aurora Cannabis
    Market Realist2 days ago

    What Analysts Recommend for Aurora Cannabis

    Analysts' January Rating Updates for TLRY, CGC, and ACB(Continued from Prior Part)Aurora Cannabis Aurora Cannabis (ACB) stock tanked nearly 8.2% after the market closed on January 16 due to the company’s announcement that it would raise ~$250

  • ACB, TLRY, and APHA Are in the Red, but CGC Continues to Gain
    Market Realist2 days ago

    ACB, TLRY, and APHA Are in the Red, but CGC Continues to Gain

    ACB, TLRY, and APHA Are in the Red, but CGC Continues to GainCannabis stocks are falling Aurora Cannabis (ACB) was trading in the red as of 11:00 AM EST today after the company announced that it would be raising $250 million worth of capital through

  • Analysts’ January Rating Updates for TLRY, CGC, and ACB
    Market Realist2 days ago

    Analysts’ January Rating Updates for TLRY, CGC, and ACB

    Analysts' January Rating Updates for TLRY, CGC, and ACBThree major stocks With a lot of action expected to boost the sentiments of cannabis investors (HMMJ), three major cannabis stocks are off to a positive start in 2019. These three stocks are

  • Planet 13 Holdings Has Returned ~30% in January: What’s Next?
    Market Realist3 days ago

    Planet 13 Holdings Has Returned ~30% in January: What’s Next?

    Planet 13 Holdings Has Returned ~30% in January: What’s Next?Stock performanceAs of January 15, Planet 13 Holdings (PLTH) (PLNHF) was trading at 1.94 Canadian dollars, which represents a rise of 30.2% since the beginning of 2019. Also, the company

  • Mid-Day Movers in the Cannabis Sector: CGC, TLRY, ACB, and More
    Market Realist3 days ago

    Mid-Day Movers in the Cannabis Sector: CGC, TLRY, ACB, and More

    Mid-Day Movers in the Cannabis Sector: CGC, TLRY, ACB, and MoreMid-day moversAround mid-day today, the major cannabis stocks were broadly positive. The Horizons Marijuana Life Sciences ETF (HMMJ) was up almost 1% around noon. Let’s look at how

  • Tilray Tanks, but Canopy Growth and Aurora Hold Their Gains
    Market Realist4 days ago

    Tilray Tanks, but Canopy Growth and Aurora Hold Their Gains

    Tilray Tanks, but Canopy Growth and Aurora Hold Their GainsTilray tanksToday, Tilray (TLRY) has tanked nearly 10.1% to $90 as of 11:45 AM EST. The stock has apparently been affected by an IPO lockup expiry, which essentially opens the door for early

  • Aphria Comments on Short Sellers and Green Growth Yet Again
    Market Realist4 days ago

    Aphria Comments on Short Sellers and Green Growth Yet Again

    Key Takeaways from Aphria's Second-Quarter Earnings(Continued from Prior Part)Criticism from short-sellersLately, Aphria (APHA) has been under fire from short sellers due to its acquisitions in international markets. Short sellers

  • How Hemp License Sets CGC on a Path to a Billion Dollars in Sales
    Market Realist4 days ago

    How Hemp License Sets CGC on a Path to a Billion Dollars in Sales

    Why Senator Schumer Is Pleased with Canopy Growth(Continued from Prior Part)A word on valueAs we discussed in the last part of this series, Canopy Growth (WEED)(CGC) recently acquired a hemp license. This license increases the fundamental value for

  • Key Takeaways from Aphria’s Second-Quarter Earnings
    Market Realist4 days ago

    Key Takeaways from Aphria’s Second-Quarter Earnings

    Key Takeaways from Aphria's Second-Quarter EarningsAphria’s earningsAphria (APHA) reported its earnings on January 11. The stock gained nearly 5.4%, which indicates that investors saw the earnings results in a positive light. In this series,

  • Market Realist5 days ago

    Checking In on Cannabis Stocks: TLRY, ACB, CGC, and More

    In the first half of January 14, Tilray (TLRY) was up 6.8% as of noon. The stock continued its upward momentum after it received a boost last week from comments by one of its largest holders. See Is Tilray Back in Action for Day Traders?

  • Cannabis Stocks Were in the Green in Second Week of 2019
    Market Realist5 days ago

    Cannabis Stocks Were in the Green in Second Week of 2019

    Cannabis Stocks Were in the Green in Second Week of 2019 ## Cannabis sector Amid strength in the broader equity market, cannabis stocks performed well last week. Between January 4 and January 11, the Horizons Marijuana Life Sciences Index ETF (HMMJ), which tracks the North American Medical Marijuana Index, has returned 17.5%, while the ETFMG Alternative Harvest ETF (MJ) returned 13.6%. In comparison, the S&P 500 Index rose 2.5% during the same period. ## Cannabis stocks Of the ten stocks considered for our analysis, eight stocks delivered positive returns, while the stock prices of two companies declined last week. During the period, Wayland Group (MRRCF) posted a strong performance with returns of 20.4%. Wayland Group was followed by The Green Organic Dutchman Holdings (TGODF) and Planet 13 Holdings (PLNHF) with returns of 17.9% and 10.4%, respectively. On January 8, The Green Organic Dutchman Holdings announced the appointment of Caroline MacCallum, an expert in cannabinoid-based medicine, and Jacques Dessureault, who has had an extensive pharmaceutical career, to its board. The optimism surrounding these appointments drove the company’s stock last week. On January 7, Planet 13 Holdings announced that its revenue and customer count at its Superstore in Las Vegas grew in December. The announcement appears to have contributed to the rise in its stock price. Also, during the same period, Origin Agritech (SEED), Curaleaf Holdings (CURLF), VIVO Cannabis (VVCIF), Trulieve Cannabis (TCNNF), and iAnthus Capital Holdings (ITHUF) have returned 9.8%, 5.2%, 5.2%, 4.2%, and 1.5%, respectively. However, the stock prices of MedMen Enterprises (MMNFF) and Acreage Holdings (ACRGF) fell by 4.9% and 1.9%, respectively, during the last week. On January 8, two of MedMen’s biggest investors, Brent Cox and Omar Mangalji, sued the company for “alleged breaches of fiduciary duty,” which led to a fall in the company’s stock price.

  • Aphria Sells Cannabis Cheaper than StatsCan’s Reported Averages
    Market Realist5 days ago

    Aphria Sells Cannabis Cheaper than StatsCan’s Reported Averages

    Aphria Sells Cannabis Cheaper than StatsCan's Reported Averages ## StatsCan report On January 9, StatsCan reported its latest findings for the recreational cannabis market after legalization. StatsCan reported that the average price recreational users paid after legalization in Canada was nearly 8.02 Canadian dollars per gram. However, this data was from a sample of about 385 submissions received by StatsCan. A more accurate place to look for pricing for recreational cannabis could be from companies such as Aphria (APHA), Canopy Growth (WEED), CannTrust (CNTTF), and Tilray (TLRY) themselves. ## Average selling price In the above chart, we see three average prices. The first one is the most recent national average price paid for recreational cannabis. The second one shows the average selling price of 6.3 Canadian dollars including excise tax for Aphria’s adult use cannabis during the second quarter. The third price is the average medical and wholesale price of 7.5 Canadian dollars including excise tax for Aphria’s medical and wholesale product. Clearly, the average selling prices for both adult use and medical cannabis was far lower than what StatsCan reported for its national averages. It is important to sell legalized cannabis at the right price for both the government and companies (HMMJ) including Canopy Growth (WEED), Cronos (CRON), and Tilray (TLRY), as one of the key reasons cited for legalizing cannabis was to eliminate the illicit market. According to the same StatsCan report, the prices in the illicit market prior to the legalization of recreational cannabis averaged 6.83 Canadian dollars.

  • Is Tilray Back in Action for Day Traders?
    Market Realist5 days ago

    Is Tilray Back in Action for Day Traders?

    Is Tilray Back in Action for Day Traders? ## Tilray rose On January 11, Tilray (TLRY) rose almost 19% and closed at $96. Tilray had its best day in 2019 after it fluctuated in 2018. Tilray became one of the hot stocks for day traders and other investors looking to make a quick buck in September when the stock reached a peak of almost $300. In the rest of 2018, Tilray lost its sheen. The stock fell as low as $65 towards the end of 2018. So, what boosted Tilray on January 11? ## Why did Tilray increase? Tilray got a boost from one of its biggest shareholders, whose lock-up period is coming to an end this week. The shareholder indicated that it intends to hold Tilray even after the lock-up period expires. According to a Bloomberg report, Privateer Holdings held nearly 76% of Tilray’s shares. A sale from Privateer Holdings would add as many as 76 million shares to the company’s float. Privateer Holdings doesn’t intend to sell its shares. The company supports Tilray’s global growth strategy. Currently, Tilray has a float of nearly ten million shares, which is significantly low compared to its peers (HMMJ). Aurora Cannabis (ACB) has 929 million shares, Canopy Growth (WEED) has 49 million shares, and Cronos Group (CRON) has 156 million shares. With little hope from Privateer Holdings regarding more shares available for trading, the company might continue to see wide swings in the price, which makes it appealing to day traders. However, Privateer Holdings doesn’t intend to sell Tilray’s share in the first half of 2019. When Privateer Holdings decides to sell Tilray’s share, it will happen in an orderly manner. For ongoing updates, visit Market Realist’s Healthcare page.

  • Cannabis Stocks: CGC, TLRY, CRON, and Others Last Week
    Market Realist5 days ago

    Cannabis Stocks: CGC, TLRY, CRON, and Others Last Week

    Cannabis Stocks: CGC, TLRY, CRON, and Others Last Week ## Major cannabis stocks For the week ending January 11, most of the major cannabis stocks ended in the positive territory. The Horizons Marijuana Life Sciences ETF (HMMJ) gained nearly 17.5% between the closing on January 4 and the closing on January 11. ## Gainers Tilray (TLRY) emerged as the biggest gainer last week. Tilray rose nearly 37% after a private equity company stated that it will keep its investments in the company through the second half of 2019. Canopy Growth (WEED) (CGC) rose 36% last week. Canopy Growth got a boost after Constellation Brands provided some visibility on its earnings within the next 18 months. Canopy Growth received coverage initiation from two major investment firms. Aurora Cannabis (ACB) gained nearly 21% last week, while Cronos Group (CRON) rose 16% between the weeks ending January 4 and January 11. Aphria (APHA), which reported its earnings last week, rose 13.8%. Supreme Cannabis (SPRWF) gained nearly 12.7%, while CannTrust (CNTTF) gained nearly 13.8%. OrganiGram (OGRMF) was also among the top gainers last week with a 10% gain. Emerald Health (EMHTF) was the only stock in the above chart that ended in the negative territory with a weekly decline of 1.3%. To learn more about the cannabis sector, read Why Green Growth Stock Rose Yesterday, Jim Cramer Made His Pick in the Cannabis Industry, and Canopy Growth: Notes from Constellation Brands’ Earnings.

  • These 3 Stocks Trounced the Top Marijuana ETFs in 2018, and Here's Why They'll Do It Again This Year
    Motley Fool6 days ago

    These 3 Stocks Trounced the Top Marijuana ETFs in 2018, and Here's Why They'll Do It Again This Year

    Repeat performances could be in store for these big marijuana winners from last year.

  • Will 2019 Be a Better Year for MedMen Enterprises?
    Market Realist8 days ago

    Will 2019 Be a Better Year for MedMen Enterprises?

    Will 2019 Be a Better Year for MedMen Enterprises? ## Stock performance On January 10, MedMen Enterprises (MMEN) (MMNFF) was trading at 4.24 Canadian dollars, representing a fall of 8.8% since its announcement of its fiscal 2019 first-quarter earnings results on November 29. The company is currently trading 36.3% higher than its 52-week low of 3.11 Canadian dollars and 57.1% lower than its 52-week high of 9.88 Canadian dollars. The pessimism surrounding cannabis stocks and the weakness in the broader equity market due to the Fed’s interest rate increase and concerns over the US government shutdown led MedMen’s stock price to fall to 3.64 Canadian dollars as of the end of the day on December 24. However, on December 24, MedMen announced that it had entered into a definitive agreement to combine its business and PharmaCann’s business under a new company called New MedMen. The transaction still requires approval from MedMen’s shareholders, and it also faces regulatory and legal hurdles. On completing the transaction, the new combined company will have a permit to operate 76 retail stores and 16 cultivation and production facilities. It will also have the license to operate in 12 states. These 12 states cover ~50% of the US population. Cowen Group expects the addressable cannabis market for these 12 states to reach $40 billion by 2030. The optimism surrounding the acquisition drove MedMen’s stock price. On January 8, two of MedMen’s biggest investors, Brent Cox and Omar Mangalji, sued the company for “alleged breaches of fiduciary duty,” leading its stock price to fall on January 9. ## Peer comparison From November 29 to January 10, MedMen’s peers Acreage Holdings (ACRG-U) (ACRGF), Planet 13 Holdings (PLTH) (PLNHF), and Curaleaf Holdings (CURA) (CURLF) returned 2.7%, -3.2%, and 10%, respectively. The Horizons Marijuana Life Sciences Index ETF (HMMJ), which tracks the North American Medical Marijuana Index, returned -1.0% during the same period. Next, let’s look at analysts’ revenue expectations for MedMen in 2019 and 2020. Continue to Next Part Browse this series on Market Realist: * Part 2 - Analysts Expect MedMen’s Revenue to Rise in 2019 and 2020 * Part 3 - Analysts Favor ‘Buy’ Ratings on MedMen Enterprises

  • Market Realist8 days ago

    Tilray Surges 20%, Aphria Reports Earnings

    Tilray Surges 20%, Aphria Reports Earnings ## Tilray surges in premarket trading Tilray (TLRY) is making new highs this morning, with the company rising nearly 21% to $97 in the premarket trading session. The company’s pop has come as the result of a statement made by private equity company Privateer Holdings, which stated that it would continue to hold TLRY shares through the first half of 2019. ## Aphria reports earnings Earlier this morning, Aphria (APHA) reported its second-quarter earnings results. The company reported net sales of 21.7 million Canadian dollars, missing analysts’ estimate of 38.8 million Canadian dollars. Its sales totaled 8.5 million Canadian dollars in the corresponding quarter a year ago in 2017. Nonetheless, the company saw sales growth of 154% and stated that the initial sales of recreational cannabis (HMMJ) had given its revenue a boost in the second quarter. The company’s adjusted gross margin contracted over the same period to 46.9% from 67.7% year-over-year, while it reported an adjusted EBITDA of -0.5 million Canadian dollars. Another key point Aphria made in its earnings call was that the company’s CEO, Vic Neufeld, and its cofounder, Cole Cacciavillani, would be transitioning out of their roles in the coming months. Aphria was down 3% in the premarket trading session. Cronos (CRON) was also trading 46 basis points lower, and Canopy Growth (WEED) was down 84 basis points.

  • Why Green Growth Stock Rose Yesterday
    Market Realist8 days ago

    Why Green Growth Stock Rose Yesterday

    On January 10, Green Growth Brands (GGB) stock popped nearly 4.9% on news of a partnership with footwear company DSW in the US. This partnership enables Green Growth Brands to sell its products through DSW’s 96 stores in the United States. This development comes after a successful test run in which Green Growth Brands sold its products in ten DSW stores. In its press announcement, Green Growth Brands said that the test run exceeded expectations. In that test run, about 74% of the products that were available on DSW’s shelf were sold, which indicates strong demand. ...

  • Canada’s Recreational Cannabis: Latest Findings from StatsCan
    Market Realist8 days ago

    Canada’s Recreational Cannabis: Latest Findings from StatsCan

    Canada's Recreational Cannabis: Latest Findings from StatsCan ## StatsCan’s findings StatsCan is a Canadian government agency that compiles and reports on key statistical data points for the Canadian economy. StatsCan released its fourth-quarter findings on the Canadian cannabis sector on January 9. StatsCan had a cautionary note when using the presented data. The data could be subject to a “potential statistical bias.” ## Prices increased In the survey, StatsCan found that the average price per gram of cannabis on October 17–December 31 rose significantly after legalization to 8.02 Canadian dollars—a price increase of nearly 17.2%. StatsCan also reported that the quantity of cannabis purchased through the legal channel averaged 8.3 grams—4.7 grams through retail and 9.1 grams through mail delivery. The quantity was almost 52% lower than an average of 17.2 grams through illegal markets. Men bought more cannabis from legal sources than women. Men bought larger quantities in the legal and illegal markets. However, StatsCan reported that the average quantities purchased by men and women were greater from the illegal market than the legal market. Only 7.7% of the sample size, which is 23 of 300 respondents, purchased cannabis for the first time. Among the 23 respondents, StatsCan found that 17 started consuming cannabis because it was legalized. There’s a lot to digest from the data for investors (HMMJ) in cannabis stocks like HEXO (HEXO), Canopy Growth (WEED), Tilray (TLRY), and Aphria (APHA).

  • Market Realist8 days ago

    Constellation Brands: Canopy Growth’s Market Share

    Canopy Growth: Notes from Constellation Brands' Earnings (Continued from Prior Part) ## Market share In Constellation Brands’ quarterly earnings call on January 9, the company estimated that Canopy Growth (WEED) (CGC) will have a market share in excess of 30% in Canada. In the following chart, you can see that Canopy Growth’s market share was at 36% based on the supply agreements signed by the company in different Canadian provinces. The remaining market share will be held by companies (HMMJ) including Tilray (TLRY), Aurora Cannabis (ACB), and Aphria (APHA). ## Infused beverage There would be unfinished business if Constellation Brands finished its earning call without discussing the infused beverage introduction in Canada. When asked by an analyst on an approximate introduction date for the infused beverage in Canada, Constellation Brands’ president and COO, Bill Newlands, said, “I’ll remind everyone, beverages are not currently available in Canada. We expect and Canopy expects that, that will change later this calendar year, but an exact date of that has not been defined yet.” Selling a cannabis-infused beverage isn’t legal in Canada. As regulators work out the details on cannabis edibles, companies will roll out their branded beverage products. The government is expected to legalize cannabis edibles in October 2019 or sooner. For more updates on the cannabis industry, visit Market Realist’s Healthcare page. Browse this series on Market Realist: * Part 1 - Canopy Growth: Notes from Constellation Brands’ Earnings * Part 2 - Cannabis Industry: Constellation Brands Is Optimistic * Part 3 - Will Canopy Growth Add Value to Constellation Brands?

  • Market Realist9 days ago

    Cannabis Sector Morning Roundup: CGC, TLRY, and APHA

    Cannabis Sector Morning Roundup: CGC, TLRY, and APHA ## Canopy Growth rises In the early morning session on January 10, Canopy Growth (CGC)(WEED) had risen 3.3% as of 10:00 AM EST. The company got a boost from Constellation Brands, which announced its quarterly earnings yesterday on January 9. Constellation Brands estimated that Canopy Growth would reach a sales target of nearly one billion Canadian dollars in the next 18 months. To learn what more Constellation Brands said about Canopy Growth, read Canopy Growth: Notes from Constellation Brands’ Earnings. Tilray (TLRY) was also moving higher this morning with a gain of nearly 5% at around 10:00 AM EST. Tilray recently got another investment form Piper Jaffray’s coverage, which somewhat increased investors’ confidence in the stock. In other news, Aphria (APHA) will be releasing its second-quarter earnings tomorrow before the market opens. To know what to expect in its earnings, read our series Aphria’s Earnings: Analysts’ Expectations Next Week. Cronos Group (CRON), another major stock (HMMJ), was up 1%, while Aurora Cannabis (ACB) was trading higher by 3.5% in the early morning session.

  • Canopy Growth: Notes from Constellation Brands’ Earnings
    Market Realist9 days ago

    Canopy Growth: Notes from Constellation Brands’ Earnings

    Canopy Growth: Notes from Constellation Brands' Earnings ## Notes from earnings Constellation Brands has invested nearly $4 billion in Canopy Growth (WEED). Constellation Brands released its earnings for the third quarter of fiscal 2019 on January 9. While the market focused on Constellation Brands’ disappointing earnings, we were glued to what the company had to say about its future with Canopy Growth. In this series, we’ll discuss the cannabis industry portion of Constellation Brands’ earnings release. ## Expectations In the earnings call, Constellation Brands provided a sales target for Canopy Growth. In the next 18 months, the sales target is expected to reach about one billion Canadian dollars. One billion is substantial for a company that had revenues of 77 million Canadian dollars in 2018. Recreational cannabis legalization has become the catalyst for the company to be able to reach the target. Analysts have a more conservative view than Constellation Brands. If we take 18 months from now until fiscal 2020, Canopy Growth will report six quarterly earnings releases. In 2020, analysts’ consensus estimate for Canopy Growth’s sales is nearly 807 million Canadian dollars. Analysts expect Canopy Growth to cross one billion Canadian dollars in 2021. The sales growth is substantial. If Canopy Growth’s earnings meet the estimates, Constellation Brands would benefit significantly from its investment. Other cannabis stocks (HMMJ) including Aurora Cannabis (ACB), Tilray (TLRY), and Cronos Growth (CRON) are also estimated to have substantial sales growth. Continue to Next Part Browse this series on Market Realist: * Part 2 - Cannabis Industry: Constellation Brands Is Optimistic * Part 3 - Will Canopy Growth Add Value to Constellation Brands? * Part 4 - Constellation Brands: Canopy Growth’s Market Share

  • Market Realist10 days ago

    Why Cannabis Stocks Are Popping Today

    Why Cannabis Stocks Are Popping Today ## Cannabis stocks are popping Several catalysts are driving cannabis stocks higher today. First, media outlets are reporting that Piper Jaffray, a highly respected investment firm, initiated coverage on the cannabis industry with an “overweight” rating on Canopy Growth (CGC) and Tilray (TLRY). Just yesterday, Cowen and Company, another well-respected investment firm, gave a bullish perspective on the US cannabis industry (HMMJ), raising sales estimates to $80 billion by 2030. Piper Jaffray expects the global industry to rise to $250 billion–$500 billion. Read US Cannabis Sector Bets Are Getting Bolder Every Day. In contrast to the above stocks, Aurora Cannabis (ACB) received a price target cut this morning from Eight Capital, and the consensus analyst estimates for Tilray’s upcoming quarterly earnings were expected to see an increase in loss per share. Read our Morning Cannabis Roundup: CGC, ACB, TLRY, and Others. At around 11:15 AM EST on January 9, Canopy Growth (CGC) (WEED) was up as much as 7%, while Aurora Cannabis (ACB) climbed by 2.2%. Tilray (TLRY), however, was weighed down by the larger expectation of loss in the upcoming quarter. HEXO (HEXO) was also trading nearly 1.6% lower. Check back for more updates.